Proteasome inhibition: a new therapeutic option in lupus nephritis?
van der Vlag
Johan
J
Division of Nephrology (464), Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands.
Berden
Jo H M
JH
D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis; D001402:B-Lymphocytes / Q000187:drug effects / Q000201:enzymology / Q000276:immunology; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D051379:Mice; D010950:Plasma Cells / Q000187:drug effects / Q000201:enzymology / Q000276:immunology; D011480:Protease Inhibitors / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000276:immunology; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex